Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 4 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.


Player Avatar mdriver78 (60.58) Submitted: 12/19/2012 8:55:22 AM : Outperform Start Price: $5.40 AMRN Score: -8.47

h this announcement, it appears that cash start flow for this biotech. Future bears watching!

"Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Chemport, Inc. as an additional Vascepa(R) (icosapent ethyl) active pharmaceutical ingredient (API) supplier.

"A key goal of Amarin is to expand our global supply chain to support expected Vascepa demand, diversify our supply base and ensure cost-efficient supply," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "The sNDA submission for Chemport is an important step toward achieving this goal.""

Featured Broker Partners